IP Library Granted Patent US 10,792,276
Granted Patent B2
US 10,792,276 · App. 16/398,956 · Granted Oct 6, 2020

Urolithins as immune response enhancers

Inventors: Anurag Singh (Crissier, CH); Davide D'Amico (Renens, CH); Penelope Andreux (Eclepens, CH); William Blanco-Bose (La Croix, CH); Christopher L. Rinsch (Morges, CH)
Assignee: Amazentis SA
A61K31/37A61K31/335A61K39/0011A61K39/145A61K39/39A61P31/16A61K2039/55A61K2039/55511A61P1/04A61P1/16A61P1/18A61P13/12A61P17/00A61P19/02A61P19/08A61P21/00A61P35/00C07D311/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,792,276
App. No.
16/398,956
Granted
Oct 6, 2020
Kind
B2
Abstract

Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.

Claims (24)

1. A method of raising an immune response to an antigen or enhancing, or augmenting an immune response to an antigen, comprising administering to a subject in need thereof an effective amount of a compound of formula (I)

wherein:

the subject is a human or an animal;

the immune response of the subject to an antigen is raised, enhanced, or augmented; and

A, B, C, D, W, X, Y and Z are each independently selected from H and OH;

or a salt thereof.

2. The method of claim 1 , wherein an immune function or immune health of the subject is improved.

3. The method of claim 1 , wherein the immune response is a response to a vaccination.

4. The method of claim 1 , wherein the enhanced immune response comprises an improvement in antibody seroconversion.

5. The method of claim 3 , wherein the subject is an elderly human person or child.

6. The method of claim 5 , wherein the subject is an elderly human aged 60 years or older.

7. The method of claim 2 , wherein the subject is immunocompromised.

8. The method of claim 1 , wherein A, C, D and Z are independently selected from H and OH; and B, W, X and Y are all H.

9. The method of claim 1 , wherein the compound of formula (I) is selected from urolithin A, urolithin B, urolithin C and urolithin D.

10. The method of claim 1 , wherein the compound of formula (I) is urolithin A.

11. The method of claim 2 , wherein A, C, D and Z are independently selected from H and OH; and B, W, X and Y are all H.

12. The method of claim 2 , wherein the compound of formula (I) is selected from urolithin A, urolithin B, urolithin C and urolithin D.

13. The method of claim 2 , wherein the compound of formula (I) is urolithin A.

14. The method of claim 3 , wherein A, C, D and Z are independently selected from H and OH; and B, W, X and Y are all H.

15. The method of claim 3 , wherein the compound of formula (I) is selected from urolithin A, urolithin B, urolithin C and urolithin D.

16. The method of claim 3 , wherein the compound of formula (I) is urolithin A.

17. The method of claim 4 , wherein A, C, D and Z are independently selected from H and OH; and B, W, X and Y are all H.

18. The method of claim 4 , wherein the compound of formula (I) is selected from urolithin A, urolithin B, urolithin C and urolithin D.

19. The method of claim 4 , wherein the compound of formula (I) is urolithin A.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2019
From: SINGH, ANURAG; D'AMICO, DAVIDE; ANDREUX, PENELOPE; BLANCO-BOSE, WILLIAM; RINSCH, CHRISTOPHER L.
To: AMAZENTIS SA
Reel/Frame 049088/0547 →
Priority Claims (2)
GB 1807051.6 · Apr 30, 2018 · national
GB 1807819.6 · May 14, 2018 · national
Continuity (1)
Related Publication 20190328703A1 · Oct 31, 2019
Cited By (6)
US 12,351,567 US 12,358,884 US 12,473,269 US 12,544,358 US 12,576,064 US 12,576,065